Modulight

1.15 EUR

+7.48 %

MODU

First North Finland

Medical Equipment & Services

Health Care

2,684 following

Compare

+7.48%

+10.58%

+19.79%

+22.99%

+23.66%

-85.48%

-89.49%

Modulight operates in the technology industry. The company designs, markets, and produces biomedical laser products used in oncology, genetics, and ophthalmology. The customers primarily consist of hospitals and corporate customers operating in medical technology. In addition to the main business, various value-added services are also offered. Their main market is the US.

Market cap

49.01M EUR

Turnover

153.83K EUR

P/E (adj.) (24e)

-6.36

EV/EBIT (adj.) (24e)

-4.67

EV/S (24e)

9.86

Dividend yield-% (24e)

Coverage

Recommendation

Reduce

Target price

0.90 EUR

Updated

22.10.2024

Disclaimer

Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 22.10.2024

Latest extensive report

Released: 21.03.2023

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

25.4

2025

Interim report Q1'25

2.5

2025

General meeting '25

22.8

2025

Interim report Q2'25

Risk

Business risk

Valuation risk

Low

High

ShowingAll content types

Regulatory press release17 hours ago

Modulight: Strong order intake and cost reductions improved cash flow despite increased R&D investments

Modulight

Analyst Commentyesterday by

Antti Siltanen

Modulight Q4'24 preview: We don't expect any major surprises

Modulight will publish its Q4 results on Friday, February 21 at 1:00 pm EET. We expect moderately growing revenue from Phase III clinical projects and ophthalmic lasers.

Modulight

Press release2/14/2025, 2:20 PM

Modulight to publish its financial statements bulletin for January–December 2024 on February 21, 2025

Modulight

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Create account

Regulatory press release12/31/2024, 9:15 AM

Modulight’s financial reporting and Annual General Meeting in 2025

Modulight

Regulatory press release12/30/2024, 2:00 PM

Change in Modulight Corporation’s holding of treasury shares and annulment of option rights

Modulight

Analyst Comment12/20/2024, 6:24 AM by

Antti Siltanen

Modulight receives order worth 0.5 MEUR

Delivery of the order is scheduled for the second half of 2025 and the first half of 2026.

Modulight

Drug development investment: Value creation through M&As and licensing agreements

Article12/19/2024, 11:07 AM by

Antti Siltanen

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron Pharmaceuticals Herantis Pharma Orion Modulight

Regulatory press release12/19/2024, 9:47 AM

Inside Information: Modulight Has Received an Order Worth EUR 0.5 Million

Modulight

Regulatory press release12/19/2024, 8:02 AM

Modulight Corporation's Shareholders’ Nomination Committee Composition

Modulight

Analyst Comment12/3/2024, 10:21 AM by

Antti Siltanen

Regulation of drug development

The third part in our series of articles on investing in Life Science companies deals with regulatory issues. Regulatory processes are demanding and time-consuming, and failure to comply can be disastrous for a drug development company.

Faron Pharmaceuticals Herantis Pharma Orion Mendus Modulight

Video12/2/2024, 2:00 PM

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Analyst Comment11/8/2024, 11:52 AM by

Antti Siltanen

Pay-Per-Treatment model brings Modulight order intake

Modulight announced on Friday that it has secured contracts with a minimum cumulative value of EUR 1.5 MEUR over the next two years. The news adds further visibility to the progress of the revenue and PPT model in the coming years

Modulight

Regulatory press release11/8/2024, 8:25 AM

Inside Information: Modulight has received PPT purchase orders worth of 1.5 million dollars

Modulight

Research10/22/2024, 6:51 AM by

Antti Siltanen

Modulight Q3'24: No clear signs of growth yet

Modulight's Q3 report showed no clear signs of a return to growth and revenue landed below expectations. Earnings and cash flow were roughly in line with our forecasts due to lower-than-expected costs.

Modulight

Analyst Comment10/18/2024, 12:41 PM by

Antti Siltanen

Modulight Q3'24 flash comment: Revenue missed expectations - profit and cash flow close to forecasts

Modulight's revenue was well below our expectations, but profit and cash flow were close to our forecasts. Revenue was negatively impacted by the transition to the PPT (pay-per-treatment) model and delays in prototype deliveries.

Modulight

Regulatory press release10/18/2024, 10:00 AM

Modulight: Cash flow development continued positive, progress with new business models

Modulight

Analyst Comment10/16/2024, 6:22 AM by

Antti Siltanen

Modulight Q3'24 preview: Eye laser and clinical studies as revenue drivers

Modulight will publish its Q3 results on Friday, October 18 at 1:00 pm EEST. We expect moderately growing revenue from Phase III clinical projects and ophthalmic lasers.

Modulight

Press release10/14/2024, 10:00 AM

Modulight

1.15

EUR

+7.48 %

Coverage

Latest research

Revenue and EBIT-%

EPS and dividend

Financial calendar

Risk

Modulight: Strong order intake and cost reductions improved cash flow despite increased R&D investments

Modulight Q4'24 preview: We don't expect any major surprises

Modulight to publish its financial statements bulletin for January–December 2024 on February 21, 2025

Join Inderes community

Inderes account

Modulight’s financial reporting and Annual General Meeting in 2025

Change in Modulight Corporation’s holding of treasury shares and annulment of option rights

Modulight receives order worth 0.5 MEUR

Drug development investment: Value creation through M&As and licensing agreements

Inside Information: Modulight Has Received an Order Worth EUR 0.5 Million

Modulight Corporation's Shareholders’ Nomination Committee Composition

Regulation of drug development

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Pay-Per-Treatment model brings Modulight order intake

Inside Information: Modulight has received PPT purchase orders worth of 1.5 million dollars

Modulight Q3'24: No clear signs of growth yet

Modulight Q3'24 flash comment: Revenue missed expectations - profit and cash flow close to forecasts

Modulight: Cash flow development continued positive, progress with new business models

Modulight Q3'24 preview: Eye laser and clinical studies as revenue drivers

Modulight to publish its interim report for January–September 2024 on October 18, 2024

Modulight Corporation: Managers' Transactions – Jari Sillanpää

Modulight Corporation: Managers' Transactions – Virpi Sillanpää